Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer

• Published in: Cancer Immunology, Immunotherapy Immunotherapy, 2005-03, Vol.54 (3), p.254-264
• Main Authors: RAMANATHAN, Ramesh K, LEE, Kenneth M, DAY, Roger, TROETSCHEL, Monica, FINN, Olivera J, MCKOLANIS, John, HILTBOLD, Elizabeth, SCHRAUT, Wolfgang, MOSER, Arthur J, WARNICK, Elizabeth, WHITESIDE, Theresa, OSBORNE, Jennifer, HYOUNG KIM
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic agents; Biological and medical sciences; Cancer Vaccines - therapeutic use; CD8-Positive T-Lymphocytes - immunology; Cell Separation; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Glycoproteins - chemistry; Hepatitis B - immunology; Humans; Hypersensitivity, Delayed; Immune System; Immunoglobulin G - chemistry; Immunoglobulin M - chemistry; Immunotherapy - methods; Lipid A - analogs & derivatives; Lipid A - therapeutic use; Male; Medical sciences; Middle Aged; Mucin-1 - chemistry; Mucin-1 - immunology; Original; Pancreatic cancer; Pancreatic Neoplasms - immunology; Pancreatic Neoplasms - mortality; Pancreatic Neoplasms - therapy; Peptides - chemistry; Pharmacology. Drug treatments; Radiotherapy, Adjuvant; Saponins - therapeutic use; T-Lymphocytes - immunology; Time Factors; Treatment Outcome
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/s00262-004-0581-1

MUC1 is a glycoprotein overexpressed in tumors as a hypoglycosylated form. A vaccine composed of a 100-amino acid peptide corresponding to five 20-amino acid long repeats, and SB-AS2 adjuvant, was tested in a phase I study for safety, toxicity, and ability to elicit or boost MUC1-specific immune responses. Patients with resected or locally advanced pancreatic cancer without prior chemotherapy or radiotherapy were eligible. Escalating doses of the peptide (100, 300, 1,000, and 3,000 mug) were admixed with SB-AS2 and administered intramuscularly every 3 weeks for three doses, in cohorts of four patients. Sixteen patients were enrolled. Common adverse effects were grade 1 flu-like symptoms, tenderness, and erythema at the injection site. Delayed-type hypersensitivity (DTH) sites showed few or no T cells prevaccination (Pre V), but increased T-cell infiltration postvaccination (Post V). There was an increase in the percentage of CD8(+) T cells in the peripheral blood Post V. An increase in total MUC1-specific antibody was seen in some patients, and several patients developed IgG antibody. Two of 15 resected pancreatic cancer patients are alive and disease free at follow-up of 32 and 61 months. MUC1 100mer peptide with SB-AS2 adjuvant is a safe vaccine that induces low but detectable mucin-specific humoral and T-cell responses in some patients. No difference was seen between different peptide doses. Further evaluation is warranted to examine the effect on disease-free survival and overall survival, especially in early disease and in the absence of immunosuppressive standard therapy.